fashion -WSS

fashion

author：explore 2025-09-30 22:41:52 - browse：82246

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Zyn nicotine pouches become unlikely player in latest culture war

explore

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Can sheer will power keep patients alive in their dying hours?

Christmas in the PICU brings some surprising joy

Medicare Advantage insurers face 0.2% cut to 2025 payments

Violet CEO on training clinicians to promote more inclusive care

What STAT readers think about the FDA and patient advocacy

focus

fashion

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Trump demands the U.S. pay no more for drugs than other countries … again

Why Medicare shouldn’t cover every FDA

Apple is now the first public company to be valued at $3 trillion

The Affordable Care Act has saved billions in health care costs

New air purifier tech could be key to improving indoor air quality

Medicare drug price negotiation hasn't dried up venture capital

Medical leaders decry Supreme Court decision on affirmative action

David Ricks of Eli Lilly: best biopharma CEO of 2023

leisure time

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Wegovy leads to weight loss. Can it treat depression, too?

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Pancreatic cancer early detection could be helped by AI

hotspot

focus

explore

focus